Italy’s Chiesi Raises Annual Guidance on Drug Sales Growth

Italian pharmaceutical company Chiesi Group said it expects to beat its financial guidance for the year, boosted by strong sales at its rare diseases unit.

“We are aiming for high single-digits of revenue growth,” Chief Executive Officer Giuseppe Accogli said in an interview, compared to a previously disclosed target of mid-single digits. He also expects to deliver a “strong” Ebitda margin for the year.